Physician profile
Laura Guadiana
NPI 1598084386
$5,195.03
in general payments reported to CMS, 2019-2025
38 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Obesity Medicine (Preventive Medicine) provider received nationally (typical 2025 total: $203).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $633 · 2021: $1,087 · 2022: $1,086 · 2023: $762 · 2024: $823 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,744 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,744.32 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $812.50 | 2019-2024 | |
| Novo Nordisk INC | $569.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $401.17 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $294.11 | 2020-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.38 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $274.50 | 2020-2025 | Veozah |
| Glaxosmithkline, LLC. | $210.44 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $202.67 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $195.67 | 2022-2023 | |
| Astrazeneca Pharmaceuticals Lp | $190.59 | 2019-2025 | Farxiga |
| Pfizer INC. | $161.86 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $144.87 | 2019-2024 | Spravato |
| Novartis Pharmaceuticals Corporation | $137.56 | 2020-2022 | |
| Vivus LLC | $124.97 | 2023 | Qsymia |
| Myovant Sciences INC. | $121.26 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Guadiana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.